These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32501511)

  • 1. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
    Maharaj AR; Wu H; Hornik CP; Balevic SJ; Hornik CD; Smith PB; Gonzalez D; Zimmerman KO; Benjamin DK; Cohen-Wolkowiez M;
    JAMA Pediatr; 2020 Oct; 174(10):e202422. PubMed ID: 32501511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.
    Lutz JD; Mathias A; German P; Pikora C; Reddy S; Kirby BJ
    Clin Pharmacol Ther; 2021 Apr; 109(4):1116-1124. PubMed ID: 33501997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects.
    Humeniuk R; Mathias A; Cao H; Osinusi A; Shen G; Chng E; Ling J; Vu A; German P
    Clin Transl Sci; 2020 Sep; 13(5):896-906. PubMed ID: 32589775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
    JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient.
    Hillaker E; Belfer JJ; Bondici A; Murad H; Dumkow LE
    Pharmacotherapy; 2020 Jun; 40(6):592-598. PubMed ID: 32281114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
    Jorgensen SCJ; Kebriaei R; Dresser LD
    Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Audio Interview: New Data on Remdesivir in Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948
    [No Abstract]   [Full Text] [Related]  

  • 9. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
    Goldman JD; Lye DCB; Hui DS; Marks KM; Bruno R; Montejano R; Spinner CD; Galli M; Ahn MY; Nahass RG; Chen YS; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wei X; Gaggar A; Brainard DM; Towner WJ; Muñoz J; Mullane KM; Marty FM; Tashima KT; Diaz G; Subramanian A;
    N Engl J Med; 2020 Nov; 383(19):1827-1837. PubMed ID: 32459919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early experience with remdesivir in SARS-CoV-2 pneumonia.
    Durante-Mangoni E; Andini R; Bertolino L; Mele F; Florio LL; Murino P; Corcione A; Zampino R
    Infection; 2020 Oct; 48(5):779-782. PubMed ID: 32418190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir for the Treatment of Covid-19 - Final Report.
    Beigel JH; Tomashek KM; Dodd LE; Mehta AK; Zingman BS; Kalil AC; Hohmann E; Chu HY; Luetkemeyer A; Kline S; Lopez de Castilla D; Finberg RW; Dierberg K; Tapson V; Hsieh L; Patterson TF; Paredes R; Sweeney DA; Short WR; Touloumi G; Lye DC; Ohmagari N; Oh MD; Ruiz-Palacios GM; Benfield T; Fätkenheuer G; Kortepeter MG; Atmar RL; Creech CB; Lundgren J; Babiker AG; Pett S; Neaton JD; Burgess TH; Bonnett T; Green M; Makowski M; Osinusi A; Nayak S; Lane HC;
    N Engl J Med; 2020 Nov; 383(19):1813-1826. PubMed ID: 32445440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
    Tempestilli M; Caputi P; Avataneo V; Notari S; Forini O; Scorzolini L; Marchioni L; Ascoli Bartoli T; Castilletti C; Lalle E; Capobianchi MR; Nicastri E; D'Avolio A; Ippolito G; Agrati C;
    J Antimicrob Chemother; 2020 Oct; 75(10):2977-2980. PubMed ID: 32607555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM
    J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans.
    Hanafin PO; Jermain B; Hickey AJ; Kabanov AV; Kashuba AD; Sheahan TP; Rao GG
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):89-99. PubMed ID: 33296558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032.
    Brooks KM; Baltrusaitis K; Clarke DF; Nachman S; Jao J; Purswani MU; Agwu A; Beneri C; Deville JG; Powis KM; Stek AM; Eke AC; Shapiro DE; Capparelli E; Greene E; George K; Yin DE; Jean-Philippe P; Chakhtoura N; Bone F; Bacon K; Johnston B; Reding C; Kersey K; Humeniuk R; Best BM; Mirochnick M; Momper JD;
    J Infect Dis; 2024 Oct; 230(4):878-888. PubMed ID: 38839047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
    Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
    Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
    Dobrovolny HM
    Virology; 2020 Nov; 550():61-69. PubMed ID: 32882638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Yao X; Ye F; Zhang M; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D
    Clin Infect Dis; 2020 Jul; 71(15):732-739. PubMed ID: 32150618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.